Renoprotective effects of HMG/CoA reductase inhibitor on patients with hyperlipidemia associated with renal insufficiency-Effect of atorvastatin by switching from other statins-

Renoprotective effects of HMG/CoA reductase inhibitor on patients with hyperlipidemia associated with renal insufficiency-Effect of atorvastatin by switching from other statins- - Renoprotective effects of atorvastatin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007703

Enrollment

Registered

2012-04-09

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

Examine the effects of exchanging to atorvastatin from other statins on renal functions

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients with micro-albuminuria complicated with dyslipidemia

Exclusion criteria

Exclusion criteria: The exclusion criteria were an age >70 years, current history of myocardial infarction and/or cerebral stroke, uncontrollable hypertension and hyperglycemia, renal failure, abnormal liver or muscle enzymes (ALT>100, ALT>100), patients who applied for other clinical trial within 3 months, expectant mother, lactating woman, patients who had taken ACE-I and/or ARB within 3 months, inappropriate patients judged by the physician in charge

Design outcomes

Primary

Measure	Time frame
Urinary podocyte	—

Countries

Japan

Contacts

Public ContactMinoru Takemoto

Chiba University Hospital Department of Medicine, Division of Diabetes, Metabolism and Endocrinology

minoru.takemoto@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026